| Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. | |
| | |
MedLine Citation:
|
PMID: 18353996 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on ambulatory blood pressure was assessed in nondiabetic patients with mild to moderate hypertension in a randomized, double-blind, placebo-controlled, 3-period crossover study. Nineteen patients on stable treatment with antihypertensive agent(s) received sitagliptin 100 mg b.i.d., 50 mg b.i.d., or placebo for 5 days, with at least a 7-day washout interval between periods. Twenty-four-hour ambulatory blood pressure, including systolic blood pressure, diastolic blood pressure, and mean arterial pressure, were monitored on days 1 and 5. Relative to placebo on day 1, the mean difference in 24-hour systolic blood pressure was -0.9 mm Hg (90% confidence interval: -2.9 to 1.1; P = .46) with sitagliptin 50 mg b.i.d. and -2.8 mm Hg (90% confidence interval: -4.9 to -0.8; P < .05) with 100 mg b.i.d. On day 5, the mean difference in 24-hour systolic blood pressure was -2.0 mm Hg (90% confidence interval: -3.5 to -0.4; P < .05) with 50 mg b.i.d. and -2.2 mm Hg (90% confidence interval: -3.7 to -0.6; P < .05) with 100 mg b.i.d. relative to placebo. For 24-hour diastolic blood pressure, there were no between-group differences in mean 24-hour diastolic blood pressure on day 1. On day 5, sitagliptin 50 mg and 100 mg b.i.d significantly (P < .05) lowered mean 24-hour diastolic blood pressure by -1.8 mm Hg (90% confidence interval: -2.8 to -0.8) and -1.6 mm Hg (90% confidence interval: -2.6 to -0.7), respectively, relative to placebo. Sitagliptin produced small but statistically significant reductions of 2 mm Hg to 3 mm Hg in 24-hour ambulatory blood pressure measurements acutely (day 1) and at steady state (day 5), and was generally well tolerated in nondiabetic patients with mild to moderate hypertension. |
| | |
Authors:
|
Goutam C Mistry; Andrea L Maes; Kenneth C Lasseter; Michael J Davies; Keith M Gottesdiener; John A Wagner; Gary A Herman |
Related Documents
:
|
19606236 - Health-related quality of life and blood pressure control in hypertensive patients with... 951896 - The hypertension of long-term hemodialysis patients: studies with an angiotensin ii ant... 6703816 - Military antishock trousers. effect on hemodialysis-induced hypotension. 2715066 - The influence of initial hemoglobin and blood pressure levels on results of radiation t... 17885326 - Effect of repeated induced airway collapse during total liquid ventilation. 8797666 - Acute hypertension, but not thrombolysis, increases the incidence and severity of hemor... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2008-03-19 |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 48 ISSN: 0091-2700 ISO Abbreviation: J Clin Pharmacol Publication Date: 2008 May |
Date Detail:
|
Created Date: 2008-04-28 Completed Date: 2008-08-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 592-8 Citation Subset: IM |
Affiliation:
|
Merck Research Laboratories, RY34-A400, 126 East Lincoln Avenue, Rahway, NJ 07065, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adolescent Adult Aged Antihypertensive Agents / administration & dosage, therapeutic use* Blood Pressure / drug effects* Blood Pressure Monitoring, Ambulatory Cross-Over Studies Dipeptidyl-Peptidase IV Inhibitors / administration & dosage, pharmacology, therapeutic use Double-Blind Method Female Humans Hypertension / drug therapy*, physiopathology Male Middle Aged Pyrazines / administration & dosage, therapeutic use* Treatment Outcome Triazoles / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Dipeptidyl-Peptidase IV Inhibitors; 0/Pyrazines; 0/Triazoles; 0/sitagliptin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation pr...
Next Document: Quantitative performance of E-Scribe warehouse in detecting quality issues with digital annotated EC...